Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

  title={Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.},
  author={Elias J Jabbour and Hagop A Kantarjian and Lina Eliasson and Amanda Megan Cornelison and D. W. Marin},
  journal={American journal of hematology},
  volume={87 7},
Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
24 Citations
23 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 24 extracted citations


Publications referenced by this paper.
Showing 1-10 of 23 references

Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia

  • M St. Charles, VK Bollu, E Hornyak
  • Blood (ASH Annual Meeting
  • 2009
Highly Influential
5 Excerpts

National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia

  • NCCN
  • 2011
1 Excerpt

A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML)

  • F Guilhot, J Coombs, O Zernovak
  • Blood (ASH Annual Meeting
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…